Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Antineoplastic Antibiotics. Found 6 abstracts

Mantia-Smaldone G, Ronner L, Blair A, Gamerman V, Morse C, Orsulic S, Rubin S, Gimotty P, Adams S. The immunomodulatory effects of pegylated liposomal doxorubicin are amplified in BRCA1--deficient ovarian tumors and can be exploited to improve treatment response in a mouse model. Gynecol Oncol. 2014 Jun;133(3):584-90.
Burtness BA, Manola J, Axelrod R, Argiris A, Forastiere AA. A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study. Ann Oncol. 2008 May;19(5):977-83.
Baselli EC, Greenberg RE. Maintenance therapy for superficial bladder cancer. Oncology (Huntingt). 2001 Jan;15(1):85-8; discussion 88-91.
Obasaju C, Manola J, Hudes GR, Khandekar JD, Citrin DL, Carbone P, Trump DL. Phase II evaluation of menogaril in advanced prostate cancer: Eastern Cooperative Oncology Group EST P-A885. Am J Clin Oncol. 2001 Apr;24(2):150-4.
Baselli EC, Greenberg RE. Intravesical therapy for superficial bladder cancer. Oncology (Huntingt). 2000 May;14(5):719-29; discussion 729-31, 734, 737.
Watson JC, Sutanto-Ward E, Osaku M, Weinstein JK, Babb JS, Sigurdson ER. Importance of timing and length of administration of angiogenesis inhibitor TNP-470 in the treatment of K12/TRb colorectal hepatic metastases in BD-IX rats. Surgery. 1999 Aug;126(2):358-63.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Antineoplastic Antibiotics

Antineoplastic Antibiotics drug therapy therapeutic use Human Male Female Transitional Cell Carcinoma Aged Mitomycin analogs & derivatives prevention & control secondary pathology Bladder Neoplasms adverse effects Survival Analysis Combined Modality Therapy Doxorubicin Interferons BCG Vaccine Antineoplastic Combined Chemotherapy Protocols Salvage Therapy Taxoids Animal Disease Models BRCA1 Genes Peripheral Nervous System Diseases Tumor Cell Line Prostatic Neoplasms Anticarcinogenic Agents Immunologic Adjuvants Non-US Gov't Support Thiotepa Time Factors chemically induced Drug Administration Schedule Sesquiterpenes Paclitaxel Hematologic Diseases therapy Polyethylene Glycols Immunomodulation genetics Squamous Cell Carcinoma Brca Adult drug effects Epirubicin adverse Pathologic Neovascularization Middle Age pharmacology Middle Aged Intravesical Administration Ovarian cancer Tumor-Infiltrating Lymphocytes US Gov't Support-PHS Head and Neck Neoplasms Animal Photosensitizing Agents Cell Survival Menogaril effects Colorectal Neoplasms Neoplasm Drug Resistance Xenograft Model Antitumor Assays Cultured Tumor Cells Antineoplastic Agents Residual Neoplasm Intravenous Infusions T-Lymphocytes Rats Ovarian Neoplasms Urologic Surgical Procedures Epothilones Mycobacterium bovis Host immunity toxicity 80 and over Aged Disease-Free Survival T cells Hormone-Dependent Neoplasms Local Neoplasm Recurrence Recurrence Experimental Liver Neoplasms Pegylated Liposomal Doxorubicin administration & dosage Mice Photochemotherapy immunology
Last updated on Monday, May 04, 2020